Equity Overview
Price & Market Data
Price: $1.73
Daily Change: $0.00 / 0.00%
Daily Range: $1.32 - $4.58
Market Cap: $119,569,464
Daily Volume: 26,690,784
Performance Metrics
1 Week: -64.62%
1 Month: -74.41%
3 Months: -73.43%
6 Months: -63.27%
1 Year: 18.49%
YTD: -73.43%
Company Details
Employees: 56
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.